Lung Cancer Therapeutics Market Growth, Trend, Demand and Forecast Lung Cancer Therapeutics Market - Global Industry
Lung Cancer Therapeutics Market - Global Industry Analysis,
Size, Share, Growth, Trends, and Forecast 2017 – 2025
Abnormal cell growth can lead to cancer. Cells that grow uncontrollably invade nearby tissues and further
spread to other parts of the body through the lymphatic system. Lung cancer, also known as lung
carcinoma, is characterized by uncontrolled cell growth in lungs. There are three major types of lung
cancer: non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor. Non-small cell lung
cancer is the common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers.
Common symptoms of lung cancer include coughing, chest pains, weight loss, and shortness of breath.
Lung cancer can be treated through various types of therapies such as chemotherapy, radiation therapy,
vaccines, and immunotherapies.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5153
According to Centers for Disease Control and Prevention (CDC), lung cancer is the primary cause of cancer
death and the second most common cancer. The global lung cancer therapeutics market is expected to
expand at a rapid pace during the forecast period due to the increase in incidence of lung cancer. Cigarette
smoking, pipes, cigar smoking, and constant exposure to asbestos are the key factors that can cause lung
cancer. Prominent factors driving the global lung cancer therapeutics market include increase in geriatric
population and rise in prevalence of unhealthy lifestyles. Availability of generic drugs, poor cancer
diagnostic facilities in many countries, high cost and the adverse effect of radiation and chemotherapies
are the factors likely to restrain the global lung cancer therapeutics market during the forecast period.
The global lung cancer therapeutics market can be segmented based on chemotherapy, targeted therapy,
radiotherapy, and geography. Based on chemotherapy, the global lung cancer therapeutics market can be
categorized into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine, and others. Chemotherapy is usually
based on the combination of drugs. In terms of targeted therapy, the global lung cancer therapeutics
market can be divided into Avastin, Tarceva, Iressa, Gilotrif, and others. Based on radiotherapy, the global
lung cancer therapeutics market can be segregated into external beam radiotherapy, internal
radiotherapy, and systemic radiotherapy.
Geographically, the lung cancer therapeutics market can be segmented into North America, Europe, Asia
Pacific, Middle East & Africa, and Latin America. North America is expected to dominate the global lung
cancer therapeutics market in the near future, due to extensive technological advancements in the
region.
Europe is anticipated to be the second largest market for lung cancer therapeutics owing to the large
government funding in the field of research and development of novel drugs and technological
advancements in the fields of cancer. The global lung cancer therapeutics market in Asia Pacific is